Figure 1 . Approved ATMPs in the EU from 2012 to 2022. Blue
boxes show ATMPs for which the sponsor is either a pharmaceutical
company or a private biotech while orange boxes are those that
originally come from an academic centre (universities and hospitals) but
developed and commercialised by a pharmaceutical company. For example,
Kymriah®, was originally developed at the University
of Pennsylvania and bought by Novartis who performed all the
pharmaceutical development and commercialisation. Filled boxes are ATMPs
that are currently authorised by the EMA while empty boxes show
withdrawn products. This figure is adapted from the CAT quarterly
highlights and approved ATMPs document.
Figure 2. Overview of the lifecycle of an ATMP (key steps of
the drug pharmaceutical development). Adapted from the slides of the
STARS Pilot III Regulatory Support project. Figure prepared with
Biorender®.